IPMK

Inositol polyphosphate multikinase · Q8NFU5 · IPMK on Sugi Atlas →

1,815 patent compounds predicted against IPMK, 1,680 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Quercetin (SCHEMBL2407213)	0.81	7/20
Quercetin (SCHEMBL8116614)	0.77	7/20
Quercetin (SCHEMBL4303275)	0.72	7/20
Tamarixetin (SCHEMBL892776)	0.82	6/20
Kaempferol (SCHEMBL5251789)	0.75	6/20
Quercetin (SCHEMBL1545849)	0.72	6/20
Luteolin (SCHEMBL8161993)	0.72	6/20
Quercetin (SCHEMBL6440211)	0.68	6/20
Quercetin (SCHEMBL10877423)	0.65	6/20
Quercetin (SCHEMBL19723)	1.00	5/20
Quercetin (SCHEMBL118425)	1.00	5/20
Quercetin (SCHEMBL22103)	0.97	5/20
Quercetin (SCHEMBL1658852)	0.97	5/20
Quercetin (SCHEMBL3786991)	0.97	5/20
Quercetin (SCHEMBL4815328)	0.97	5/20
Quercetin (SCHEMBL6756842)	0.97	5/20
Quercetin (SCHEMBL9512499)	0.97	5/20
Quercetin (SCHEMBL9958875)	0.97	5/20
Quercetin (SCHEMBL10323960)	0.97	5/20
Quercetin (SCHEMBL288466)	0.92	5/20

Clinical trials — most relevant to IPMK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Inositol in Letrozol Resistant PCOS Women	PHASE2/PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Reformulated F75 Milk to Treat Severe Acute Malnutrition	PHASE2/PHASE3	COMPLETED
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Biological Effects of Quercetin in COPD	PHASE1/PHASE2	UNKNOWN
Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study	nan	WITHDRAWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Myoinositol Effect on Asprosin Levels	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)	nan	RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a IPMK binder may also engage these)

Protein	Name	Similarity
Q99NI4	—	0.993	Q99NI4 →
Q7TT16	—	0.991	Q7TT16 →
Q9R0U1	—	0.977	Q9R0U1 →
IP6K2	Inositol hexakisphosphate kinase 2	0.975	landscape →
Q80V72	—	0.973	Q80V72 →
Q95221	—	0.973	Q95221 →
Q6GR37	—	0.963	Q6GR37 →
Q7TQE7	—	0.962	Q7TQE7 →
Q3LAC4	—	0.960	Q3LAC4 →
Q8BWD2	—	0.960	Q8BWD2 →
E1C3P4	—	0.960	E1C3P4 →
MALT1	Mucosa-associated lymphoid tissue lymphoma translocation protein 1	0.960	landscape →
Q9ESL4	—	0.960	Q9ESL4 →
Q5R803	—	0.959	Q5R803 →
Q8BHD4	—	0.959	Q8BHD4 →
Q5F480	—	0.959	Q5F480 →
Q9UPW5	—	0.958	Q9UPW5 →
O88377	—	0.958	O88377 →
PIP4K2B	Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	0.958	landscape →
PARN	Poly(A)-specific ribonuclease PARN	0.958	landscape →
Q641K1	—	0.958	Q641K1 →
SHPRH	E3 ubiquitin-protein ligase SHPRH	0.958	landscape →
F1QDI9	—	0.957	F1QDI9 →
Q9NXL9	—	0.957	Q9NXL9 →
Q5R4N7	—	0.957	Q5R4N7 →
Q5RED8	—	0.957	Q5RED8 →
Q99MU3	—	0.956	Q99MU3 →
Q69ZK0	—	0.956	Q69ZK0 →
Q13572	—	0.956	Q13572 →
Q80XI4	—	0.956	Q80XI4 →